Melanoma GEP: where risk scores help—and where they do not
Dr. Singh explains why stage III melanoma is a poor fit for GEP, how a 9.7% nodal-risk estimate needs context, and when ctDNA adds surveillance in practice.
Topic
Topic
Dr. Singh explains why stage III melanoma is a poor fit for GEP, how a 9.7% nodal-risk estimate needs context, and when ctDNA adds surveillance in practice.